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Perfluorooctanoatic acid (PFOA, or C8)
is one member of the class of man-made 
 perfluorocarbon (PFC) compounds. PFOA 
exists as an alkyl acid (PFOA), an ammo-
nium salt [ammonium perfluorooctanoate 
(APFO)], or as a dissociated conjugate base 
[perfluorooctanoate (PFO)]. A closely related 
PFC is perfluorooctanesulfonate (PFOS; C8 
sulfonate, or C8S). Additional, related PFCs 
include C5 [perfluoropentanoic acid (PFPeA)], 
C6 [perfluorohexanoic acid (PFHxA)], C6 sul-
fonate [perfluorohexane sulfonate (PFHS)], 
C7 [perfluoroheptanoic acid (PFHpA)], 
C9 [perfluorononanoic acid (PFNA)], C10 
[perfluorodecanoic acid (PFDA)], C11 [per-
fluoroundecanoic acid (PFUnA)], and C12 
[perfluorododecanoic acid (PFDoA)]. PFCs are 
used as plasticizers, wetting agents, and emulsi-
fiers during the manufacture of fluoro polymers, 
including products that impart nonstick heat 
resistance to cookware or breathable yet water-
proof properties to fabrics. PFCs may also result 
from the metabolism or environmental break-
down of fluorinated telomers, including chemi-
cals used to coat commercial food packaging 
and for stain-resistant treatment for fabrics and 
clothing. PFOA may also be a residual impurity 
in personal care products.
PFCs and health. PFOA and other PFCs 
persist in the environment and are found in 
groundwater and surface water worldwide 
(Yamashita et al. 2008). They are present 
in blood and other tissues of animal species 
throughout the world, including remote regions 
(Tao et al. 2006). Recent publications have 
extensively reviewed and summarized the 
known toxicologic properties, environmental 
distribution, and potential health concerns 
related to PFOA (Kennedy et al. 2004; Kudo 
and Kawashima 2003; Lau et al. 2007). Animal 
toxicology studies have suggested potential sup-
pression of humoral immunity, neuroendocrine 
effects, and  exposure-related gestational and 
developmental effects. Cumulative evidence 
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Background: The C8 Health Project was created, authorized, and funded as part of the settlement 
agreement reached in the case of Jack W. Leach, et al. v. E.I. du Pont de Nemours & Company (no. 
01-C-608 W.Va., Wood County Circuit Court, filed 10 April 2002). The settlement stemmed from 
the perfluorooctanoic acid (PFOA, or C8) contamination of drinking water in six water districts in 
two states near the DuPont Washington Works facility near Parkersburg, West Virginia. 
oBjectives: This study reports on the methods and results from the C8 Health Project, a popula-
tion study created to gather data that would allow class members to know their own PFOA levels 
and permit subsequent epidemiologic investigations. 
Methods: Final study participation was 69,030, enrolled over a 13-month period in 2005–2006. 
Extensive data were collected, including demographic data, medical diagnoses (both self-report and 
medical records review), clinical laboratory testing, and determination of serum concentrations of 
10 perfluorocarbons (PFCs). Here we describe the processes used to collect, validate, and store these 
health data. We also describe survey participants and their serum PFC levels.
results: The population geometric mean for serum PFOA was 32.91 ng/mL, 500% higher than 
previously reported for a representative American population. Serum concentrations for perfluoro-
hexane sulfonate and perfluorononanoic acid were elevated 39% and 73% respectively, whereas 
perfluorooctanesulfonate was present at levels similar to those in the U.S. population. 
conclusions: This largest known population study of community PFC exposure permits new evalu-
ations of associations between PFOA, in particular, and a range of health parameters. These will con-
tribute to understanding of the biology of PFC exposure. The C8 Health Project also represents an 
unprecedented effort to gather basic data on an exposed population; its achievements and limitations 
can inform future legal settlements for populations exposed to environmental contaminants.
key words: C8, environmental contamination, perfluorocarbons, PFOA, toxic tort settlement. 
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from mammalian animal studies has suggested 
that the liver is an important target organ. 
Reported hepatotoxic effects include liver 
enlargement, hepato cellular adenomas, and per-
oxisome proliferation [specifically peroxisome 
proliferator-activated receptor (PPAR)-α], pos-
sibly suggesting a possible nongenotoxic carci-
nogenic mechanism for PFCs.
Additionally, combined evidence supports 
that PFCs generally, and PFOA and PFOS 
specifically, are present in the sera of diverse 
human populations (Lau et al. 2007). In the 
United States, almost all National Health and 
Nutrition Examination Survey (NHANES) 
samples contained these chemicals, with 
a U.S. population median of 5 ppb PFOA. 
Both PFOA and PFOS concentrations were 
higher in the serum of men and those with 
higher education (Calafat et al. 2007a, 2007b). 
Although potential sources of human exposure 
continue to be investigated, current, known 
sources of PFOA exposure generally include 
drinking water, household dust, and food or 
migration from food packaging (in particular, 
commercial and fast-food/take-out packages) 
and cookware (Lau et al. 2007). Occupational 
studies have shown elevated worker exposures 
in manufacturing processes that use PFOA 
or PFOS (Emmett et al. 2006; Olsen et al. 
2003).
Human population studies, predominantly 
medical surveillance studies of male American 
workers exposed occupationally to PFOA or 
PFOS, have reported inconsistent findings 
(Lau et al. 2007). Although some studies have 
reported associations between exposure and 
cancer (bladder and prostate in particular), 
lipids, liver enzymes, and some thyroid hor-
mones, follow-up studies and others have 
either contradicted earlier findings or found 
evidence suggesting explanation through 
confounding parameters (Lau et al. 2007). 
Maternal serum and neonatal cord blood stud-
ies have implicated an association of PFOA 
or PFOS with birth weight (Apelberg et al. 
2007; Washino et al. 2009), but there are also 
contradictory findings in high-exposure popu-
lations (Nolan et al. 2008). The half-life of 
PFOS and PFOA in human sera has been 
reported as approximately 5 and 3.5 years, 
respectively (Olsen et al. 2007).
In a review process that remains ongoing, 
the U.S. Environmental Protection Agency 
(EPA) is considering evidence and classifica-
tion of PFOA as a likely human carcinogen 
(U.S. EPA 2006). The U.S. EPA’s PFOA 
Stewardship Program proscribes PFOA, 
PFOA precursors, and related, higher homo-
logue chemicals from emissions and products 
by 2015 (U.S. EPA 2009). In the European 
Union, the use of PFOS and derivatives 
was stopped in 2000 and banned in 2008, 
although PFOA use remains largely unregu-
lated (Jensen and Leffers 2008).
Origin of the C8 Health Project. The 
C8 Health Project can be traced to legal 
actions taken by a local family. A portion of 
this family’s farmland was sold to DuPont 
(E.I. du Pont de Nemours & Co.) in 1984, 
which subsequently converted the land parcel 
into a site to dispose of waste products from 
PFC manufacturing from their Washington 
Works plant. The family alleged that the 
(then unknown) chemicals from the land-
fill were responsible for family illness, wild-
life death, and the death of almost 300 head 
of their cattle [see Supplemental Material, 
Note 1 (doi:10.1289/ehp.0800379.S1 via 
http://dx.doi.org)]. The family agreed to a 
confidential settlement with DuPont in 2001; 
associated legal activities, including indepen-
dently commissioned studies and reports filed 
by government agencies, served to provide 
environmental data and to heighten local 
awareness of the exposure, coincident with an 
emerging scientific literature.
The following points summarize key 
events in the almost two-decade time line 
leading to the C8 Health Project:
•	Cumulative	evidence	detected	PFOA	con-
tamination of water supplies along the 
mid-Ohio River Valley (approximately 
1984–2004). Water pollution was attrib-
uted to direct industrial releases from 
DuPont’s Washington Works plant into 
the Ohio River, a principal source of pub-
lic drinking water, and airborne pollution 
more broadly contaminated water tables 
and aquifer systems, with subsequent con-
tamination of well water, an important 
drinking water source in a rural commu-
nity [see Supplemental Material, Note 2 
(doi:10.1289/ehp.0800379.S1)].
•	August	2001 through April 2002: Thirteen 
plaintiffs filed a lawsuit against DuPont, 
which was subsequently certified as a class 
action, Jack W. Leach v. E.I. du Pont de 
Nemours & Co. (Civil Action No. 01-C-
608), filed in the Wood County, West 
Virginia, Circuit Court. The “Class” was 
defined as individuals, in West Virginia or 
Ohio, whose drinking water had been con-
taminated by quantifiable levels of PFOA.
•	November	2004:	A	multicomponent $107 
million pretrial settlement between the 
Class and DuPont was reached. Complete 
settlement terms are part of the public 
record. Key provisions included the follow-
ing: a $70 million award for Class mem-
bers, of which $20 million was required to 
be used for health and education projects; 
provision of water treatment technologies 
to remove PFOA from the water supply 
of the six affected water districts; and for-
mation of an independent panel of three 
scientific experts to carry out a community 
study and determine if there is a “probable 
link” [see Supplemental Material, Note 3 
(doi:10.1289/ehp.0800379.S1)] between 
PFOA exposure and human disease.
The settlement broadly outlined terms 
of agreement but did not detail how they 
were to be satisfied. Post hoc negotiations 
between settling parties resolved that the 
health and education projects and Class pay-
ments would be achieved through a popula-
tion-wide health study of the Class, initially 
known as the “Settlement Class Health & 
Education Project” and later the “C8 Health 
Project” (the Project). An independent com-
pany, Brookmar, Inc., was created to design, 
publicize, and implement the Project under 
court supervision. Three epidemiologists 
(the C8 Science Panel) were appointed to 
determine the presence or absence of what 
the court termed a “probable link” between 
PFOA exposure and human disease [see 
Supplemental Material, Note 3 (doi:10.1289/
ehp.0800379.S1)]. In addition to Project 
data, the C8 Science Panel is to include data 
de novo, prospective community studies that 
they proposed and are conducting.
The Project faced significant implementa-
tion challenges, including Court and popula-
tion expectations for rapid time lines as well as 
absence of precedent for the likely scale of the 
community project. Project participation was 
the established route for Class members to 
benefit from the settlement, but neither Class 
size nor participation was known a priori. 
Accordingly, Brookmar, Inc. developed pro-
cedures to accommodate rurality, shift work-
ers, eligible Class members no longer living in 
the area, a wide range in participant age and 
mobility, a deliberately short survey period, 
community apprehension expressed regard-
ing data privacy and concern about adverse 
effects on insurability and even employabil-
ity, and the desire for participants to receive 
personalized information about laboratory 
results and general information about Project 
findings. The data collection methodology 
implemented by Brookmar, Inc., agreed to 
implicitly or explicitly by counsel for the set-
tling parties, is described below.
C8 Health Project Methods
Eligibility. Class eligibility was defined by 
exposure to contaminated water, a combina-
tion of geographic and concentration criteria, 
and exposure duration. Key criteria included 
a) exposure to contaminated water from any of 
six public water districts [two in West Virginia, 
four in Ohio; see Supplemental Material, 
Figure 1 (doi:10.1289/ehp.0800379.S1)] or 
from private water sources within the geo-
graphical boundaries of the public water sources 
which contained ≥ 0.05 ppb PFOA, and b) the 
ability to document a minimum 12 months of 
exposure to contaminated water between 1950 
and 3 December 2004, at primary residence, 
place of employment, or school.
C8 Health Project methods and results
Environmental Health Perspectives • volume 117 | number 12 | December 2009 1875
Participants supplied documentation 
demonstrating both their identity and expo-
sure using a combination of Court-defined 
acceptable documents. Brookmar, Inc. inde-
pendently verified the authenticity of docu-
ments with the issuing agency, and identity 
documentation was examined to ensure that 
participants were enrolled only once. Scanned 
document copies became part of the partici-
pant’s Project electronic data record.
Data components. Four types of data were 
collected: a health survey, self-reported anthro-
pometric measurements, a blood sample, and a 
medical chart review to validate selected self-re-
ported diagnoses. In identifying clinical labora-
tory tests and selecting diagnoses for validation, 
priority was given to those with potential asso-
ciations with PFC exposure as reported in the 
scientific literature. Clinical laboratory tests 
included serum lipid, immune, and inflamma-
tory markers; liver, kidney, and thyroid func-
tion; complete blood count; serum electrolytes 
and protein; and endocrine function, includ-
ing insulin and glucose [see Supplemental 
Material, Note 4 (doi:10.1289/ehp.0800379.
S1)]. Validated medical diagnoses included 
heart disease, cancers, thyroid disease, neuro-
logic disorders, inflammatory and autoimmune 
disorders, and pregnancy complications [see 
Supplemental Material, Note 5 (doi:10.1289/
ehp.0800379.S1)].
The health survey gathered demographic 
data; current and historic residential and 
employment information, including water 
source and use; personal medical diagnoses, 
treatments including medications, and physi-
cal symptoms; family medical history; preg-
nancy history and pregnancy-related outcomes 
for women; and information about lifestyle 
and health behaviors. Participants also self-
reported their own height, weight, and blood 
pressure. Brookmar, Inc. contracted with a 
separate company to independently pilot test 
the survey, and revisions were made based on 
pilot-test findings. The final version of the sur-
vey was accepted by the settling parties. The 
survey, a list of the clinical laboratory tests, 
and the 18 medical diagnoses verified by med-
ical record review are publically available on 
The C8 Health Project WVU Data Hosting 
Website (C8 Health Project 2009).
Enrollment. An independent information 
technology (IT) company was contracted to 
build and manage informatics solutions that 
addressed Class security concerns and created a 
web-based mechanism for Project registration 
and health survey completion. Participants 
could alternatively register in person and use 
paper-based surveys. After registration and 
completion of the health survey, participants 
received instructions regarding requirements 
for demonstrating eligibility and making an 
appointment at a Project data-collection site. 
Standard data quality-assurance techniques 
for survey data, including a quota for data 
duplicate entry for paper-based surveys and 
 electronic-based logic rules (e.g., limited-
 answer menus) for Web-based surveys, were in 
place for the health survey.
Data collection procedures. Temporary 
modular office units were established in each 
water district, staffed with nurses, phleboto-
mists, and intake personnel, and equipped 
for venipuncture, blood processing, and 
short-term record and blood sample storage. 
Participants could schedule appointments 
between 0730 and 1930 hours at the location 
of their convenience. Because of both feasibil-
ity and participant considerations, fasting was 
not required for phlebotomy, although self-re-
ported fast duration was collected to facilitate 
interpretation of laboratory results.
At in-person appointments, participants 
submitted eligibility documentation and the 
water district indicated by the exposure doc-
umentation provided was recorded; this was 
usually but not always the source of greatest 
exposure. Project staff verified demographic 
data, current residential information, and com-
pletion of the health survey and asked par-
ticipants to report their current height, weight, 
and blood pressure. Participants voluntarily 
submitted a blood sample.
Each verified participant received $150 for 
completing the health survey and an additional 
$250 for providing a blood sample (regardless 
of sample quantity or quality). The payment 
amount reflected the compensation intentions 
of the settlement and remuneration for Project 
participation expenses.
Blood sample processing and labora-
tory methods. Blood samples were obtained 
and processed at individual data collection 
sites. Samples were drawn into four tubes 
per participant, with a maximum 35 mL for 
adults and 26 mL for children. Tubes were 
spun, aliquotted, and refrigerated until ship-
ping. For limited-volume samples, serum was 
aliquotted with priority for PFC analysis. 
Samples were shipped on dry ice daily from 
each data collection site to the laboratory 
retained to measure serum PFCs. The clinical 
laboratory contracted to perform the clinical 
chemistry analysis picked up samples daily 
from each data-collection site. Additionally, 
an aliquot of serum from each participant 
was frozen and subsequently stored in a 
Project tissue bank.
Clinical laboratory tests were performed at 
a large, independent, accredited clinical diag-
nostic laboratory (LabCorp, Inc., Burlington, 
NC, USA). A customized health level 7 inter-
face generated immediate, on-site laboratory-
specific identification numbers and tube labels 
and permitted subsequent electronic trans-
fer of clinical laboratory results directly into 
the Project data system. Clinical laboratory 
tests and quality assurance were performed in 
accordance with the accreditation standards 
required of this laboratory.
The primary laboratory performing PFC 
analysis (Exygen Research Inc., State College, 
PA, USA) was selected based on its ability to 
meet U.S. Food and Drug Administration 
guidelines for bioanalytical method validation, 
a lower limit of quantification of 0.5 ng/mL, 
and 96-well-plate–based technology allow-
ing for high-throughput capability. This was 
also the laboratory of record for a previously 
reported, independently performed study 
of residents in one water district included 
in the Project (Emmett et al. 2006). The 
PFOA quantification and validation meth-
odology used by this laboratory has been pre-
viously detailed (Flaherty et al. 2005). The 
analytic protocol used for the Project was a 
modification of this methodology. Briefly, 
the technique used a protein precipitation 
extraction together with reverse-phase high-
performance liquid chromatography/tandem 
mass spectrometry. Spectrometric detection 
was performed using a triple quadrupole mass 
spectrometer in selected reaction monitor-
ing mode, monitoring for the individual m/z 
transitions for each of the 10 PFCs and the 
13C-PFOA surrogate. Results for the 10 PFCs 
measured were incorporated into the Project 
information system through a Windows-based 
program [see Supplemental Material, Note 6 
(doi:10.1289/ehp.0800379.S1)].
PFC quality assurance. A two-tiered qual-
ity assurance program was implemented con-
sisting of a) evaluation of test reliability in 
the primary lab (intralab reliability) with the 
use of blank samples, samples spiked with a 
known PFC concentration, and participant 
duplicate samples, and b) use of a second, 
external laboratory (AXYS Analytical Services 
Ltd., Sidney, BC, Canada) to determine 
PFC concentrations for participant duplicate 
samples (interlab reliability). This laboratory, 
with the ability to monitor 10 individual 
PFCs and a lower limit of quantification of 
0.2 ng/mL, employed analytic methods pre-
viously described (Kuklenyik et al. 2004; 
Taniyasu et al. 2005). Briefly, the technique 
used solid-phase extraction on a weak anion-
exchange column followed by reverse-phase 
high-performance liquid  chromatography/
mass spectrometry. Spectrometric detection 
was performed using a triple quadrupole mass 
spectrometer in selected reaction monitoring 
mode, monitoring individual m/z transitions 
for each of the target PFCs, the 13C-PFOA, 
13C-PFOS, and 13C-PFDA surrogates and the 
13C-PFOA and FOUEA (13C-2H-perfluoro-2-
-decenoic acid) instrument internal standards.
To assess method performance at the pri-
mary laboratory, quality control samples in 
the form of two control serum blanks, two lab 
control spikes in control serum, and two sam-
ple duplicates were included with each batch 
Frisbee et al.
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of 90 samples analyzed. 13C-PFOA (surro-
gate) was also added to every sample before 
extraction to assess lab preparation. Bulk con-
trol blanks and spikes were prepared at the 
primary lab and sent to the sampling sites. 
They were then blindly returned with every 
shipment of samples for analysis to assess stor-
age, transport, and laboratory preparation 
effects. For these quality control samples, the 
Project IT system generated in-line dummy 
identification numbers and two sets of lab-
ready, bar-coded phlebotomy tube labels. Site 
nurses aliquotted two sets of sample tubes, 
and both were included as part of the standard 
shipment to the primary laboratory. Based on 
a data collection site-specific sampling plan, 
samples were also automatically identified by 
the Project IT system for the secondary lab. 
Labels and tubes were generated similarly, as 
were sample aliquots. Results from quality 
assurance samples were segregated from the 
main, participant database post hoc by the IT 
company, the only group unblinded to iden-
tification numbering.
During analysis of quality assurance 
results, a consistent difference between the pri-
mary and secondary laboratory was detected 
(~ 30%) for samples obtained during the first 
4 months of the Project. Investigation and 
additional, targeted intra- and interlab retest-
ing confirmed these directional (higher) differ-
ences. Per a court filing, Exygen discussed the 
cause as a problem of initially prepared samples 
used for internal calibration [see Supplemental 
Material, Note 7 (doi:10.1289/ehp.0800379.
S1)]. Affected samples (~ 25,000) were retested 
using serum stored in the Project tissue bank; 
quality assurance testing, including sample 
duplicates and replaced spiked and calibration 
samples, was also repeated. Retested results 
demonstrated a consistent decrease from initial 
results and increased consistency with the sec-
ondary lab. All analytic results presented here 
include only retested values for those affected 
serum samples.
For quantitative assessment of quality 
assurance test results, final test values were 
matched to participant quality assurance val-
ues for the primary or secondary lab. Results 
reported as less than the limit of detection 
(LOD) were treated conservatively and 
excluded from quality assurance analyses. 
Agreement between two measures was assessed 
with the absolute difference, percent difference 
(absolute difference between values divided by 
value means), and coefficient of variation (SD 
divided by mean), which were then summa-
rized (mean and median) across the matched-
samples results.
Validation of select medical diagnoses. 
Participants self-reporting one of the 18 tar-
geted diagnoses were asked to provide the 
time and location of diagnosis. After obtain-
ing appropriate record release consent, 
Brookmar, Inc., requested a copy of support-
ing documentation from a medical record 
or pathology report from health care provid-
ers. Cooperating providers were compensated 
$10 per necessary page. For approximately 
36,000 validated diagnoses, the following 
was recorded: self-reported diagnosis; sup-
port (confirmation), nonsupport (negation), 
missing (records not obtained), or substitu-
tion (i.e., documentation supported a differ-
ent diagnosis); the alternate diagnosis where 
appropriate; and type of documentation used 
for verification. Review of medical records 
and determination of diagnostic verifica-
tion were performed by nurses employed by 
Brookmar, Inc.
Consenting procedures. Brookmar, Inc., 
required that participants read (and “check” 
affirmatively) an introductory section of the 
health survey that explained the purpose and 
procedures of the Project, and risks and bene-
fits of participation. This language is publically 
available as part of the survey tool. All par-
ticipants submitting a voluntary blood sample 
completed the standard consent and release 
forms of the clinical laboratory contracted 
for phlebotomy. Brookmar, Inc. obtained a 
separate consent form for the release of medi-
cal records necessary for diagnosis validation, 
which was subsequently mailed (along with 
a cover letter and specific documentation 
request) to the health care provider identified 
by the participant.
The Project group at West Virginia 
University and the C8 Science Panel obtained 
institutional review board (IRB) approval from 
their own institutions permitting access to dei-
dentified Project data. With assistance from 
Brookmar, Inc., the C8 Science Panel obtained 
additional IRB approval allowing access to 
identified data, which facilitates contacting par-
ticipants for enrollment in follow-up studies.
Implementation. After input by the settling 
parties, Brookmar, Inc. used multiple avenues 
to publicize the Project. Communications 
about Project eligibility requirements, enroll-
ment, data collection procedures, time line, 
and remuneration included a series of open 
meetings conducted in five of the six water 
districts, Project Web site messages, a phone 
bank, and press conferences with local media, 
an important source of information through-
out the duration of the Project.
Brookmar, Inc. also maintained communi-
cation with local health care providers. Meetings 
were conducted to inform the medical commu-
nity about Project procedures, including medi-
cal record requests, as well as the information 
that participants would be provided pursuant to 
their Project participation.
Efforts to ensure full access for interested 
participants included multiple sites, 12-hr 
daily appointment availability, and disability 
accommodation including handicap access 
and assistance completing the health survey. 
Brookmar, Inc. also coordinated remote data 
collection for those otherwise eligible Class 
members unable to travel to a data collec-
tion site (e.g., those no longer living in the 
vicinity). For these participants, eligibility 
documentation was submitted via mail, fol-
lowed by remote completion of the health 
survey and a personal telephone interview. 
These remote participants then completed 
phlebotomy at an identified, local, accredited 
laboratory. Of the total participants, approxi-
mately 600 participated via these procedures 
(Flensborg P, personal communication).
Brookmar, Inc. was unable to accommo-
date participants cognitively unable to com-
plete the survey (and without a representative 
to accurately complete it on their behalf) or 
those physically unable to travel to a phlebot-
omy site. Thus, these groups are likely under-
represented among Project participants.
Data analysis and reporting. Participants 
were mailed individualized results for clinical 
lab tests, including laboratory normal ranges 
and flags for abnormal findings. For severely 
abnormal values, emergency flags triggered 
a personal communication from Brookmar, 
Inc. personnel with advice to seek prompt 
medical attention. Participants also received a 
report of their PFC values.
Upon complet ion of  the Project , 
Brookmar, Inc. filed an electronic data set 
with the Wood County Court in May 2008. 
The data set included the health survey, clini-
cal laboratory and PFC values, an image of 
eligibility documents, and record of payment. 
To protect participant privacy, the presid-
ing judge subsequently sealed the data set. A 
mechanism is currently being sought wherein 
an agency, likely of the federal government, 
would maintain and make accessible a dei-
dentified data set for public research use.
The C8 Science Panel is conducting 
analyses using the Project cross-sectional 
data collected and is also conducting its own 
independent, environmental and population-
based studies, also financed by the settlement. 
For consenting participants, the C8 Science 
Panel is able to link Project-collected data 
with follow-up and longitudinal studies. A 
description of ongoing studies is available on 
the C8 Science Panel’s web site (C8 Science 
Panel 2009). 
A tissue bank of participant frozen serum 
was established at West Virginia University in 
which samples are stored, handled, and accessed 
in a manner consistent with the IRB protocol 
governing the West Virginia University Tissue 
Bank. The sera can be linked to deidentified 
Project data and may be used for further stud-
ies related to human PFC physiology.
Brookmar, Inc. contracted with the 
West Virginia University School of Medicine 
to report to the general public descriptive 
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summaries of results from the Project. Summary 
data are reviewable at a web site established for 
that purpose (C8 Health Project 2009). 
The C8 Science Panel and the West 
Virginia University Project group are pre-
paring and submitting analyses of associa-
tions between PFCs and health outcomes, 
intended for peer-reviewed journals. These 
will form part of the evidence that will assist 
the C8 Science Panel in meeting their Court-
appointed obligation to determine “probable 
links” [see Supplemental Material, Note 3 
(doi:10.1289/ehp.0800379.S1)] between 
PFOA exposure and health outcomes.
Data cleaning. In the first phase of data 
cleaning, the IT company ensured that ques-
tion responses were consistent with question 
“skip patterns” and menu options, as well as 
ensuring consistent coding and formatting 
for question responses. For the deidentified 
data set, text fields were scrubbed to elimi-
nate potentially identifying information. In 
the second phase of data cleaning, completed 
collaboratively by the C8 Science Panel and 
West Virginia University Project team, con-
tinuous variables were examined and decision 
rules were created for outliers and missing val-
ues. Lab-generated error messages for samples 
that could not be analyzed were deleted and 
results set to “null.” For clinical lab results 
either lower or higher than the LOD, values 
were replaced with 50% below or above the 
lower or upper LOD, respectively.
Though serum samples were analyzed for 
10 PFCs, not all PFCs were detectable in all 
samples tested. Four PFCs (PFHS, PFOA, 
PFOS, PFNA) were detectable in almost all 
(> 97%) samples; for these PFCs, test results 
reported as less than the LOD were substi-
tuted with 0.25 ng/mL (50% of the lower 
LOD of 0.5 ng/mL). Three PFCs (PFHxA, 
PFHpA, PFDA) were detectable in approxi-
mately 50% of the samples; results for these 
PFCs are reported with and/or without sub-
stitution for values reported as less than the 
LOD. Three PFCs (PFPeA, PFUnA, PFDoA) 
were detectable in only a negligible portion 
of the tested samples and are not reported 
here or included in further analyses. Thus, 
results reported here include 7 of the 10 tested 
PFCs (PFHS, PFOA, PFOS, PFNA, PFHxA, 
PFHpA, PFDA).
Estimation of participation rates. Total 
Project participation was estimated by water 
district as the number of participating resi-
dents divided by the total contemporaneous 
population in that water district. Water district 
population was estimated using 2005–2006 
Census population estimates for block groups, 
the smallest Census geographic unit that could 
be accurately identified. Block groups inter-
secting with water districts were determined, 
and the population of each block group was 
apportioned to the water district based on the 
ratio of water district area to block group area 
within each block group. The number of par-
ticipants resident in each water district was 
based on the assigned water district, that for 
which the participant presented qualifying 
eligibility documents, and self-reported resi-
dence at the time of enrollment. Participation 
estimates for each water district was estimated 
for age and gender strata.
Results
Project enrollment totaled 69,030. Approxi-
mately 80% completed registration and the 
health survey online (Flensborg P, personal 
communication). PFC and clinical laboratory 
analyses were available for > 65,000 partici-
pants. Although children < 10 years of age had 
highest proportion without available blood 
analyses (almost one-third), laboratory data 
were nevertheless available for > 3,400 of these 
children. Consistent with regional demogra-
phy, > 97% of participants identified them-
selves as white, and educational attainment and 
income levels were lower than national aver-
ages. Participants ranged in age from 1.5 years 
to > 100 years, with a mean ± SD age of 39.1 ± 
19.9 years [see Supplemental Material, Table 1 
(doi:10.1289/ehp.0800379.S1)].
Twenty-six percent of adults (≥ 18 years 
of age at enrollment) reported current smok-
ing, and an additional 26% reported former 
smoking. A substantial proportion of children 
(63.3%) and adults (69.1%) lacked a regular 
exercise program. Further, 39% of children 
were classified as being at-risk or already over-
weight based on body mass index (BMI) per-
centile, and 69% of adults were classified as 
overweight or obese based on BMI. However, 
because BMI calculations were completed 
using self-reported height and weight, they 
may underestimate actual population pro-
portions. These demographic and health risk 
data are generally consistent with estimates 
for Appalachia from nationally representa-
tive data sources (Halverson et al. 2004) [see 
Supplemental Material, Table 2 (doi:10.1289/
ehp.0800379.S1)].
At the time of enrollment, most par-
ticipants reported current residence in Ohio 
(52%) or West Virginia (45%); 63% of par-
ticipants were resident in a qualifying water 
district at the time of their participation. 
Average monthly enrollment in the Project 
was 5,310, with enrollment peaking in 
January 2006 (8,003 participants). The largest 
proportion of participants qualified through 
Lubeck Public Service District (24.6%), 
followed by Tuppers Plains (20.4%) [see 
Supplemental Material, Table 3 (doi:10.1289/
ehp.0800379.S1)].
As shown in Table 1, an estimated 80.3% 
of the population resident in the water dis-
tricts during the enrollment period partici-
pated in the Project, with a slightly higher 
proportion of women compared with men 
participating. Participation by water district 
ranged from 70.6% of the resident popu-
lation in Tuppers Plains to almost 92% in 
the Village of Pomeroy. The age groups with 
the lowest estimated participation were the 
elderly (> 80 years of age) and young children 
(< 4 years of age).
Serum analysis results for 10 PFCs 
(PFPeA, PFHxA, PFHS, PFHpA, PFOA, 
Table 1. Estimated percent participation by water district.
Participants
City of 
Belpre 
(Ohio)
Tuppers 
Plains 
(Ohio)
Little Hocking 
Water 
Association 
(Ohio)
Lubeck Public 
Service District 
(West Virginia)
Mason County 
(West Virginia)
Village of 
Pomeroy 
(Ohio) Total
Age group (years)
 0–4 39.6 54.2 54.8 38.5 39.5 36.2 45.5
 5–10 79.8 71.7 81.8 72.3 79.8 87.7 77.0
 11–14 85.6 73.7 90.7 92.2 95.8 88.6 87.2
 15–19 101.9 82.0 90.7 107.5 96.9 110.2 94.6
 20–24 99.6 72.5 77.6 81.0 90.0 98.9 82.8
 25–29 88.2 74.6 84.5 73.2 90.5 86.7 81.9
 30–34 87.6 76.1 92.9 81.6 93.7 92.7 86.1
 35–39 87.3 76.7 90.8 94.5 94.6 103.2 88.7
 40–44 94.8 75.7 86.2 100.1 91.4 94.9 88.4
 45–49 94.6 71.3 85.0 89.6 90.8 109.7 85.4
 50–54 85.8 79.9 84.8 79.1 83.3 102.5 82.8
 55–59 89.3 69.6 84.1 89.5 78.1 98.8 81.2
 60–64 98.3 71.3 82.2 96.8 82.8 101.6 85.1
 65–69 89.4 67.7 88.8 91.3 78.8 88.6 82.0
 70–74 90.5 57.7 78.6 84.4 74.0 94.3 75.6
 75–79 79.8 54.2 55.2 65.1 58.3 82.6 62.1
 ≥ 80 51.8 35.4 41.9 39.8 31.0 63.2 40.1
Total 85.6 70.6 82.3 83.9 82.3 91.6 80.3
Total ≥ 20 87.8 70.2 82.6 85.2 83.1 94.8 81.0
Sex
 Male 85.0 69.6 80.9 82.8 79.9 89.2 78.8
 Female 86.1 71.6 83.8 85.0 84.8 93.6 81.8
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PFOS, PFNA, PFDA, PFUnA, PFDoA) were 
available for 66,899 participants. Table 2 sum-
marizes the proportion of tested samples with 
a detectable PFC concentration and the num-
ber of samples for which 50% of the lower 
LOD was substituted.
Table 3 reports population summary sta-
tistics for the seven PFCs, stratified by sex 
and age groups. Because of population homo-
geneity, stratification by ethnicity was not 
performed. Figure 1 highlights patterns by age 
and sex in the four widely detectable PFCs 
(PFHS, PFOA, PFOS, PFNA). For each, 
median concentrations were higher in males 
in most age groups. For PFOA and PFOS 
(Figure 1A,B), population median concentra-
tions demonstrated a J-shaped pattern, with 
higher values in younger age groups, lowest 
values in young- to middle-adult age groups, 
and highest population concentrations in 
older adult age groups. For PFHS and PFNA 
(Figure 1C,D), the highest population median 
concentrations were observed in children.
Figure 2 compares Project results for 
these same four PFCs with results from two 
nationally representative NHANES samples. 
An important difference between NHANES 
and Project results is the inclusion of children 
< 12 years of age in the Project, although this 
Project age group is likely to have a mini-
mal impact on overall population results in 
a sample size > 65,000. For all PFCs except 
PFOS, serum concentrations reported for 
the Project exceeded NHANES results. The 
largest differences were observed for PFOA, 
where the Project population had more than 
a 500% (1999–2000) or 700% (2003–2004) 
larger geometric mean. Smaller but still sub-
stantial differences were also observed for 
PFHS [57.1% (1999–2000) and 73.6% 
(2003–2004) larger] and PFNA [178% 
(1999–2000) and 39% (2003–2004) larger]. 
In contrast, the Project population had a 
36.8% (1999–2000) and 7.1% (2003–2004) 
lower geometric mean for PFOS.
Table 3. Population serum concentrations for seven PFCs (ng/mL).
Age/sex Measure PFHxAa PFHxAb PFHS PFHpAa PFHpAb PFOA PFOS PFNA PFDAa PFDAb
< 12 years
 Female Mean 0.9 1.3 10.6 1.1 1.4 73.0 22.6 1.9 0.5 0.7
Median 0.7 1.0 6.1 0.7 1.0 30.7 19.9 1.6 0.5 0.6
Geometric mean 0.7 1.1 6.5 0.7 1.1 34.8 19.7 1.7 0.4 0.7
SD 0.9 1.0 13.0 1.3 1.5 120.1 12.7 1.4 0.3 0.2
 Male Mean 1.0 1.3 12.6 1.1 1.5 82.1 24.6 1.9 0.5 0.7
Median 0.7 1.0 6.9 0.7 1.0 35.1 21.7 1.6 0.5 0.6
Geometric mean 0.7 1.1 7.4 0.7 1.1 39.1 21.5 1.7 0.4 0.7
SD 1.0 1.0 18.3 1.3 1.5 129.1 13.4 1.1 0.3 0.3
 Total Mean 1.0 1.3 11.6 1.1 1.4 77.6 23.6 1.9 0.5 0.7
Median 0.7 1.0 6.4 0.7 1.0 32.6 20.7 1.6 0.5 0.6
Geometric mean 0.7 1.1 7.0 0.7 1.1 36.9 20.6 1.7 0.4 0.7
SD 1.0 1.0 15.9 1.3 1.5 124.9 13.1 1.3 0.3 0.3
12–19 years
 Female Mean 0.8 1.4 6.2 0.7 1.2 51.0 20.1 1.4 0.5 0.7
Median 0.5 1.0 3.7 0.3 0.9 22.1 18.0 1.3 0.4 0.6
Geometric mean 0.5 1.1 4.0 0.5 1.0 25.1 17.6 1.3 0.3 0.7
SD 1.0 1.2 9.5 0.8 0.9 85.2 11.0 0.7 0.4 0.3
 Male Mean 0.9 1.4 8.3 1.0 1.5 68.4 23.4 1.6 0.3 0.7
Median 0.6 1.0 4.9 0.6 1.0 30.2 20.5 1.5 0.5 0.7
Geometric mean 0.6 1.1 5.3 0.6 1.2 33.9 20.6 1.5 0.3 0.7
SD 1.3 1.5 11.8 1.2 1.4 104.9 12.7 0.8 0.4 0.3
 Total Mean 0.9 1.4 7.3 0.9 1.3 59.9 21.8 1.5 0.3 0.7
Median 0.6 1.0 4.3 0.6 0.9 25.7 19.3 1.4 0.5 0.6
Geometric mean 0.6 1.1 4.6 0.6 1.1 29.3 19.1 1.4 0.3 0.7
SD 1.2 1.4 10.8 1.0 1.2 96.2 12.0 0.7 0.4 0.3
20–39 years
 Female Mean 0.8 1.4 3.0 0.5 1.0 42.3 16.6 1.4 0.3 0.8
Median 0.3 1.0 2.2 0.3 0.8 17.0 14.8 1.2 0.5 0.6
Geometric mean 0.5 1.1 2.2 0.4 0.9 19.8 14.0 1.2 0.3 0.7
SD 1.0 1.2 3.0 0.6 0.8 118.3 9.7 0.8 0.4 0.4
 Male Mean 1.0 1.5 5.3 0.6 1.2 76.5 24.3 1.7 0.4 0.8
Median 0.6 1.0 3.8 0.3 0.8 28.3 22.2 1.6 0.5 0.7
Geometric mean 0.6 1.2 3.8 0.4 1.0 33.4 20.7 1.6 0.5 0.7
SD 1.4 1.6 7.6 0.7 1.0 208.1 12.8 0.8 0.4 0.8
 Total Mean 0.9 1.4 4.0 0.5 1.1 58.1 20.1 1.5 0.6 0.8
Median 0.5 1.0 2.9 0.3 0.8 21.8 18.1 1.4 0.5 0.7
Geometric mean 0.6 1.2 2.9 0.4 0.9 25.2 16.8 1.4 0.3 0.7
SD 1.2 1.4 5.7 0.7 0.9 166.6 11.9 0.8 0.4 0.6
Continued
Table 2. Availability of detectable serum concentrations for PFCs shown as the number (%) of samples.
PFC
No. (%)  
with detectable 
concentration
No. (%)  
with concentration 
< LOD
No. (%)  
with substitution of 50% 
of LOD (0.25 ng/mL)
PFPeA 3,247 (4.9) 63,652 (95.2) 0 (0.0)
PFHxA 35,574 (53.2) 31,326 (46.8) 0 (0.0)
PFHS 65,499 (97.9) 1,400 (2.1) 1,400 (2.1)
PFHpA 25,095 (37.5) 41,804 (62.5) 0 (0.0)
PFOA 66,857 (99.9) 42 (0.1) 42 (0.1)
PFOS 66,600 (99.6) 299 (0.5) 299 (0.5)
PFNA 65,348 (97.7) 1,551 (2.3) 1,551 (2.3)
PFDA 30,996 (46.3) 35,903 (53.7) 0 (0.0)
PFUnA 5,835 (8.7) 61,064 (91.3) 0 (0.0)
PFDoA 488 (0.7) 66,411 (99.3) 0 (0.0)
Denominator is total possible samples (66,899).
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Unadjusted, nonparametric Spearman’s rho 
rank-order correlation analysis was performed 
for 21 pairings (seven PFCs) for the overall 
population. In general, correlations between 
the PFCs were low. Modest correlations 
(~ 30%) were observed between the pairings of 
PFHS–PFOA, PFHS–PFNA, PFOA–PFOS, 
and PFOS–PFDA. Larger correlations were 
observed between PFHpA and PFOA (~ 40%), 
PFHS and PFOS (~ 50%), PFOS and PFNA 
(~ 50%), and PFNA and PFDA (~ 60%). 
No discernable differences in correlations pat-
terns were observed between adults and chil-
dren or between sexes [data not shown; see 
Supplemental Material, Figure 2 (doi:10.1289/
ehp.0800379.S1)].
Table 4 reports serum PFC concentrations, 
weighted by age and sex, stratified by qualifying 
water district. Participants in Little Hocking 
Water Association had the highest levels of 
PFOA, > 70% higher than the next group, 
participants with private wells. For all PFCs 
other than PFOA, the 157 participants qualify-
ing through contaminated private wells had the 
highest serum concentrations. Participants in 
Lubeck Public Service District had the highest 
reported values for PFHxA, PFOS, PFNA, and 
PFDA. The highest values of PFHS were found 
in participants in the City of Belpre, Ohio.
Table 5 summarizes results for the quality 
assurance analysis. The highest agreements, 
both intralab (within the primary lab) and 
interlab (between the primary and second-
ary lab), were observed for PFHS, PFOA, 
PFOS, and PFNA. The median intralab dif-
ference for PFOA and PFOS was 5.5% and 
4.06%, respectively, whereas the median 
interlab difference for PFOA and PFOS was 
16.7% and 14.01%, respectively. The least 
agreement, either intra- or interlab agreement 
was observed for PFHxA. For PFHpA and 
PFDA, intralab but not interlab agreement 
was observed.
Discussion
This unique and large survey resulted from 
the pretrial settlement agreement of a class 
action lawsuit and a court-supervised health 
study of a population (n = 69,030) exposed to 
sustained environmental contamination with 
PFOA. The demographic characteristics and 
health behaviors of the participants reflect that 
of the affected, mostly rural, Appalachian com-
munities: predominately white, with levels of 
education and income lower than the national 
average, and higher rates of obesity and other 
health risk behaviors such as smoking and 
inactivity. Challenges posed by the defini-
tion of the Class, specifically the prolonged 
(50-year) exposure period and inclusion of 
residential, employment, and school-based 
exposure, preclude an exact determination 
of the total eligible population. However, a 
reasonable approximation suggests that 80% 
of the current population in affected water 
districts participated in the Project, although 
37% of Project participants resided outside 
an affected water district at the time of their 
Project enrollment. It is probable that a com-
bination of public concern about chemical 
contamination and monetary compensation 
contributed to participation. The high rates 
of population participation and the high rate 
(estimated at 80%) of online (vs. paper sur-
vey) enrollment and completion of the health 
Table 3. Continued
Age/sex Measure PFHxAa PFHxAb PFHS PFHpAa PFHpAb PFOA PFOS PFNA PFDAa PFDAb
40–59 years
 Female Mean 0.8 1.4 3.3 0.5 1.1 80.2 20.8 1.5 0.5 0.8
Median 0.5 1.0 2.4 0.3 0.8 25.7 17.7 1.3 0.3 0.7
Geometric mean 0.5 1.1 2.3 0.4 0.9 30.4 16.9 1.3 0.4 0.7
SD 1.0 1.1 3.7 0.8 1.2 260.7 14.2 0.8 0.4 0.4
 Male Mean 0.9 1.4 4.7 0.6 1.2 120.4 26.6 1.6 0.5 0.8
Median 0.5 1.0 3.4 0.3 0.8 37.7 23.5 1.5 0.3 0.7
Geometric mean 0.6 1.2 3.5 0.4 1.0 43.8 22.3 1.5 0.4 0.7
SD 1.1 1.2 16.8 0.8 1.2 339.0 16.7 0.9 0.8 1.1
 Total Mean 0.9 1.4 4.0 0.5 1.2 99.4 23.6 1.6 0.5 0.8
Median 0.5 1.0 2.9 0.3 0.8 30.7 20.5 1.4 0.3 0.7
Geometric mean 0.6 1.1 2.8 0.4 0.9 36.2 19.3 1.4 0.4 0.7
SD 1.0 1.2 11.9 0.8 1.2 301.4 15.7 0.9 0.6 0.9
≥ 60 years
 Female Mean 0.8 1.3 4.7 0.7 1.4 107.0 28.2 1.5 0.5 0.8
Median 0.3 1.0 3.3 0.3 0.9 41.0 24.2 1.3 0.3 0.7
Geometric mean 0.5 1.1 3.4 0.4 1.0 44.2 22.9 1.3 0.4 0.7
SD 0.9 1.0 5.3 1.1 1.6 199.9 19.7 0.8 0.4 0.4
 Male Mean 0.9 1.5 4.6 0.6 1.3 120.8 30.3 1.5 0.5 0.8
Median 0.3 1.0 3.4 0.3 0.9 42.8 26.1 1.4 0.3 0.7
Geometric mean 0.5 1.2 3.4 0.4 1.0 47.2 24.7 1.3 0.4 0.7
SD 1.1 1.4 5.3 0.9 1.3 394.1 23.2 0.9 0.4 0.5
 Total Mean 0.8 1.4 4.7 0.6 1.3 113.8 29.2 1.5 0.5 0.8
Median 0.3 1.0 3.3 0.3 0.9 41.9 25.1 1.4 0.3 0.7
Geometric mean 0.5 1.1 3.4 0.4 1.0 45.7 23.7 1.3 0.4 0.7
SD 1.0 1.2 5.3 1.0 1.4 311.7 21.5 0.8 0.4 0.5
Total population
 Female Mean 0.8 1.4 4.3 0.6 1.2 68.8 20.7 1.5 0.5 0.8
Median 0.5 1.0 2.7 0.3 0.8 23.6 17.6 1.3 0.3 0.7
Geometric mean 0.5 1.1 2.8 0.4 1.0 27.9 17.0 1.3 0.4 0.7
SD 1.0 1.1 6.2 0.8 1.2 190.6 14.1 0.8 0.4 0.4
 Male Mean 0.9 1.4 5.9 0.7 1.3 98.2 26.0 1.7 0.5 0.8
Median 0.6 1.0 3.8 0.3 0.9 33.7 22.9 1.5 0.3 0.7
Geometric mean 0.6 1.2 4.0 0.4 1.0 39.4 21.9 1.5 0.4 0.7
SD 1.2 1.4 12.8 0.9 1.3 284.3 16.5 0.9 0.6 0.8
 Total Mean 0.9 1.4 5.1 0.6 1.2 82.9 23.3 1.6 0.5 0.8
Median 0.5 1.0 3.2 0.3 0.9 28.2 20.2 1.4 0.3 0.7
Geometric mean 0.6 1.1 3.3 0.4 1.0 32.9 19.2 1.4 0.4 0.7
SD 1.1 1.3 10.0 0.9 1.2 240.8 15.6 0.9 0.5 0.7
aSubstitution with 50% of LOD for values reported as < LOD. bNo substitution for values reported as < LOD.
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survey in a rural, poor area may provide useful 
lessons for future population surveys.
As anticipated, study serum concentrations 
of PFOA, the identified environmental con-
taminant, deviated markedly from those of a 
representative, national sample in all affected 
water districts. The unadjusted population geo-
metric mean of 28.2 (median, 32.91) ng/mL 
was 6- to 8-fold higher than nationally rep-
resentative values from the NHANES study. 
However, observations of serum concentrations 
for PFHS and PFNA that were higher than 
national samples but concentrations for PFOS 
lower than national samples were not antici-
pated. The distribution and pattern of PFHS 
and PFNA concentrations is not similar to that 
of PFOA, suggesting a possible exposure source 
other than the facility identified as the source of 
PFOA exposure. Comparisons between these 
two studies are interpreted within the context 
of possible differences in laboratory analytic 
techniques (although both studies used solid-
phase extraction followed by high-performance 
liquid chromatography/tandem mass spectrom-
etry) and measurement accuracy across a broad 
spectrum of concentrations.
Discernible sex differences for PFOA 
serum levels in most age groups are consistent 
with national findings in less exposed popu-
lations. The findings of higher serum con-
centrations of PFCs in children, particularly Figure 1. PFC concentrations stratified by age and sex: (A) PFOA, (B) PFOS, (C) PFHS, and (D) PFNA.
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Figure 2. Geometric means (ng/mL) for PFC serum concentrations for C8 Health Project results [versus two NHANES samples (2003–2004; 1999–2000)]: PFOA (A), 
PFOS (B), PFHS (C), and PFNA (D). 
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for PFHS and PFNA, warrant further study. 
Although these findings are unadjusted for 
potential confounders, higher concentrations 
in the youngest age groups is counter to tra-
ditional expectations of biologic burden paral-
leling cumulative environmental exposure. 
The observation that the highest popu-
lation burden of PFOA was found in the 
Little Hocking Water Association district is 
consistent with water quality measurement 
reports from the affected water districts [many 
of which are publically available; also see 
Supplemental Material, Note 2 (doi:10.1289/
ehp.0800379.S1)]. However, the population 
PFOA results for Little Hocking are substan-
tially lower than those previously reported in 
a smaller sample of Little Hocking residents 
(age- and sex-adjusted mean of 228 ng/mL 
reported here vs. 448 ng/mL; Emmett et al. 
2006). Although the reasons for these differ-
ences are not clear, representativeness of the 
samples and study time periods are possible 
explanations. The same laboratory performed 
PFOA analysis in each study.
Table 4. Age- and sex-adjusted serum PFC concentrations by water district (ng/mL).
Water district PFHxAa PFHxAb PFHS PFHpAa PFHpAb PFOA PFOS PFNA PFDAa PFDAb
City of Belpre (Ohio)
 Mean 0.86 1.41 5.82 0.64 1.10 42.96 23.18 1.50 0.47 0.73
 SE 0.01 0.02 0.11 0.01 0.02 2.48 0.16 0.01 0.01 0.01
Little Hocking Water Association (Ohio)
 Mean 0.85 1.39 5.70 1.15 1.86 227.59 23.47 1.60 0.50 0.77
 SE 0.01 0.02 0.09 0.01 0.01 2.03 0.14 0.01 0.01 0.01
Lubeck Public Service District (West Virginia)
 Mean 1.02 1.51 5.58 0.61 1.05 92.36 24.96 1.64 0.55 0.82
 SE 0.01 0.01 0.08 0.01 0.01 1.78 0.12 0.01 0.00 0.01
Mason County (West Virginia)
 Mean 0.72 1.28 4.15 0.38 0.83 16.00 23.01 1.59 0.45 0.72
 SE 0.01 0.02 0.09 0.01 0.02 2.06 0.14 0.01 0.01 0.01
Tuppers Plains (Ohio)
 Mean 0.84 1.38 4.48 0.43 0.91 42.07 22.29 1.50 0.53 0.74
 SE 0.01 0.02 0.08 0.01 0.02 1.96 0.13 0.01 0.04 0.01
Village of Pomeroy (Ohio)
 Mean 0.83 1.38 4.25 0.38 0.83 15.96 20.97 1.46 0.47 0.69
 SE 0.02 0.03 0.17 0.01 0.04 3.83 0.25 0.02 0.00 0.02
Private Well (West Virginia or Ohio)
 Mean 0.65 1.88 9.27 0.82 1.48 132.56 26.15 1.67 0.40 0.81
 SE 0.09 0.16 0.79 0.07 0.14 18.41 1.22 0.07 0.01 0.08
aSubstitution with 50% of LOD for values reported as < LOD. bNo substitution for values reported as < LOD. 
Table 5. Summary of intra- and interlab quality assurance.
Intralab comparisonsa Interlab comparisonsb
Compound/measure
Primary lab 
test results 
(ng/mL)
Primary lab 
QA sample 
(ng/mL)
Absolute 
difference
Percent 
difference
Coefficient 
of variation
Primary lab test 
results (ng/mL)
Secondary lab 
QA sample 
(ng/mL)
Absolute 
difference
Percent 
difference
Coefficient 
of variation
PFHxA
 No. of samples 664 612 574 574 574 1,180 All values 
reported as 
< LOD
NA NA NA
 Mean 1.3 1.3 0.3 18.3% 0.1 1.2
 Median 1.0 0.9 0.1 11.8% 0.1 0.9
PFHS
 No. of samples 1,236 1,241 1,234 1,234 1,234 2,561 2,319 2,316 2,316 2,316
 Mean 4.6 4.6 0.4 9.4% 0.1 4.9 4.6 1.3 28.8% 0.2
 Median 3.1 3.1 0.2 4.9% 0.0 3.5 3.2 0.8 23.9% 0.2
PFHpA
 No. of samples 446 434 410 410 410 1,074 583 572 572 572
 Mean 1.2 1.2 0.1 8.5% 0.1 1.5 1.4 0.8 44.3% 0.3
 Median 0.9 0.9 0.1 4.2% 0.0 1.0 0.9 0.5 42.0% 0.3
PFOA
 No. of samples 1,269 1,269 1,269 1,269 1,269 2,603 2,599 2,599 2,599 2,599
 Mean 77.3 80.4 9.7 10.1% 0.1 134.5 129.7 27.1 21.0% 0.2
 Median 25.3 25.3 1.4 5.2% 0.0 43.9 39.3 6.9 16.7% 0.1
PFOS
 No. of samples 1,261 1,261 1,260 1,260 1,260 2,594 2,588 2,588 2,588 2,588
 Mean 22.9 23.2 2.0 8.4% 0.1 22.3 22.7 3.9 17.4% 0.1
 Median 19.5 19.8 0.7 4.1% 0.0 19.4 19.6 2.6 14.0% 0.1
PFNA
 No. of samples 1,246 1,243 1,240 1,240 1,240 2,539 2,329 2,314 2,314 2,314
 Mean 1.6 1.6 0.2 9.0% 0.1 1.6 1.3 0.4 28.7% 0.2
 Median 1.4 1.4 0.1 6.5% 0.1 1.4 1.2 0.3 24.9% 0.2
PFDA
 No. of samples 566 570 516 516 516 1,200 409 371 371 371
 Mean 0.8 0.8 0.1 6.9% 0.1 0.8 0.8 0.3 33.8% 0.2
 Median 0.7 0.7 0.0 0.0% 0.0 0.7 0.6 0.2 28.6% 0.2
NA, not applicable; QA, quality assurance. 
aComparison between matched samples for main test results and blinded, duplicate quality assurance samples sent to the primary lab. bComparison between matched samples for 
main test results and blinded, duplicate quality assurance samples sent to the secondary lab. 
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Although the highest serum concentrations 
of PFOA were observed in Little Hocking, 
it is interesting that higher burdens of other 
PFCs were found in other water districts. 
Investigating the association between water 
PFC concentrations and serum PFC concen-
trations and investigating the distributions of 
occupational contributions are beyond the 
scope of the present report. Further work is 
under way to model occupational, temporal, 
spatial, and temporal–spatial variation in water 
PFC levels, including differences between pub-
lic water supplies and private wells and the 
association with serum PFC levels.
Correlations between the different PFCs 
were generally modest and without discern-
able age or sex patterns. Presently, the mean-
ing of these correlations are unclear and will 
likely need to be interpreted later, within 
the context of a better understanding of pat-
terns of cumulative exposure, environmental 
accumulation, and physiologic metabolism of 
these chemicals across the life span.
Previous studies have reported on the com-
plexity of PFC determination (van Leeuwen 
et al. 2006). Although intralab measurements 
demonstrated reasonable stability, interlab 
measurements showed larger divergence. It 
is not surprising that measurements from the 
Project, which at times processed > 7,000 sam-
ples per month, would not achieve the same 
level of accuracy as federally funded projects 
with smaller sample sizes and smaller ranges 
of exposure. Spearman testing of quality-
 assurance results demonstrates that rank order 
is highly preserved for intra- and interlabora-
tory comparisons.
The large size of this cohort, together 
with the broad range of serum PFC values, 
provides unique opportunities for investigat-
ing associations between PFCs and human 
health. Although the prevalence study design 
inherently limits causal inference, the Project 
remains the largest and broadest study to date 
of associations between PFC exposure and 
human health. Subcohorts from this popu-
lation, to be followed over time, have been 
identified and the C8 Science Panel has 
already begun enrollment in longitudinal 
studies. A multivariable analysis of factors 
determining PFOA levels in the population 
has been conducted and submitted for pub-
lication (Steenland et al. 2009). Additional 
targeted analyses investigating associations 
between PFCs and specific clinical chemistries 
and disease endpoints are already under way 
and will be reported elsewhere.
Conclusion
The data from the 69,030 C8 Health Project 
participants provide valuable information on 
serum PFC concentration, demographic fac-
tors, clinical chemistry and self-reported dis-
ease in a population with a high participation 
rate. Ongoing work investigating the inter-
relationships between them will provide clues 
about possible etiologic relationships, within 
the limitations of the prevalence study design. 
In addition, they provide a valuable baseline 
characterization of this population for sub-
sequent, prospective studies.
The results, therefore, have the potential 
to improve the current understanding of the 
biology of PFC exposure and are unprece-
dented among toxic tort settlements, most 
of which simply provide compensation for 
the Class without attempting to generate use-
ful health and exposure data or assess health 
effects. As an innovative effort to gather data 
on an exposed population, the C8 Health 
Project can also serve as a model for future 
legal settlements for populations exposed 
involuntarily to environmental contaminants.
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